Puerto Rico's health secretary says the island has recorded its first Zika-related death amid an outbreak of the mosquito-borne virus. » Read More
A huge Hewlett Packard Enterprise project hopes to use massive data sets to better craft medical treatments and medicines for patients.
If there are inflation winds in the air, it would be hard to tell by worker paychecks.
Aetna CEO and Chairman Mark Bertolini talked to CNBC about earnings, drug prices and needed changes to Obamacare.
The pharmacy benefits manager is looking to partner with retail pharmacies that do the best job at keeping diabetes patients healthy.
Abbott Labs said it agreed to St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
Creating Facebook was a bold move, but CEO Mark Zuckerberg just proposed what he said is an even bolder one.
Drugmaker AbbVie said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.
Outgoing Valeant CEO Michael Pearson plans to tell a U.S. Senate panel that it was a "mistake" to jack up the price of two life-saving heart drugs.
Boston Scientific rose after the firm reported better-than-expected quarterly results.
Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline's sales figures 8 percent.
The ex-Citigroup chair and his family foundation have donated $185M to the UCSF to establish the UCSF Weill Institute for Neurosciences.
The 300 million pain prescriptions written last year equal a $24B market, but it's not a market evenly divided around the globe.
Valeant, whose stock has plunged amid probes into its drug pricing, is too mired in debt to recover, an analyst said.
BP's message to other oil companies in the first quarter was loud and clear, CNBC's Jim Cramer says.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
Advisers to the FDA voted on Monday not to recommend approval of possibly the first drug for Duchenne muscular dystrophy, the New York Times reports.
Eli Lilly reports lower-than-expected earnings due largely to heavy spending on research.
Scientists are one step closer in harnessing the power of genome sequencing to help improve the diagnosis and treatment of autism.
For doctors and nurses in a growing number of hospitals, worrying about security when they input data into computers requires a balancing act.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Get the best of CNBC in your inbox